Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
GHRP-6 vs IGF-1 LR3
An educational, source-based comparison of GHRP-6 and IGF-1 LR3 — how each peptide works, what it's researched for, and what to know before going deeper.
A hexapeptide ghrelin receptor (GHS-R1a) agonist that stimulates pituitary GH release and increases appetite via central ghrelin pathways. One of the earliest GH-releasing peptides studied.
- Endogenous GH pulse stimulation
- Appetite stimulation in cachexia models
- Cardioprotective signaling (preclinical)
- • Increases appetite and may elevate cortisol/prolactin more than newer secretagogues.
- • Not FDA-approved; banned by WADA.
A modified form of insulin-like growth factor-1 with an Arg3 substitution and N-terminal extension that reduces binding to IGFBPs, dramatically extending its half-life and free fraction in circulation.
- Muscle protein synthesis (preclinical)
- Tissue repair signaling
- Cell-culture growth applications
- • Hypoglycemia risk via insulin-receptor cross-activity.
- • Not FDA-approved for human therapeutic use; banned by WADA.
GHRP-6 vs IGF-1 LR3 — Key differences
- Class: GHRP-6 is classified as Growth Hormone Axis, while IGF-1 LR3 is Growth Factor.
- Primary research focus: GHRP-6 — endogenous gh pulse stimulation; IGF-1 LR3 — muscle protein synthesis (preclinical).
- Tag: Growth hormone · Appetite vs Growth · Recovery.